Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC Partnerships will employ Vaccinex’s ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...